Scholarlink

<p>Per- and polyfluoroalkyl substances (PFAS) are human-made chemicals used in various manufactured products that accumulate in the environment and human bodies. We examined associations between serum PFAS levels and obesity or obesity-related clinical conditions using data from participants in Okinawa Island, a region in Japan with high PFAS exposure. We conducted a cross-sectional study using blood samples and clinical data from outpatients in a large primary care clinic. Linear regression analysis investigated the relationship between serum PFAS levels and body mass index (BMI) or other obesity-related clinical conditions. We also conducted modified Poisson models with robust standard errors analysis with serum PFAS levels for overweight, obesity, dyslipidemia, and hypertension. Of 399 participants, mean serum levels of perfluorooctanoic acid (PFOA) and perfluorooctane sulfonate (PFOS) were 2.80&#xa0;ng/mL (SD, 1.93) and 7.56&#xa0;ng/mL (SD, 5.83), respectively. Increased serum levels of PFAS were not associated with higher BMIs. Higher serum levels of perfluorohexane sulfonate (PFHxS) were related to a lower level of high-density lipoprotein cholesterol (HDLC) [Beta coefficient: − 1.90&#xa0;ng/mL (95% CI − 3.33 to − 0.48)]. No adverse associations were found between higher serum PFAS levels and triglycerides, alanine transaminase, or low-density lipoprotein cholesterol. Only high serum PFHxS had a statistically significant odds ratio of 1.91&#xa0;ng/mL (95% CI, 1.08–3.38; p = 0.04) on dyslipidemia, but no other adverse relations were found between PFAS levels and overweight, obesity, and hypertension. Greater PFAS levels were not associated with obesity in our participants. However, PFHxS and PFOA were related to lower levels of HDLC, and PFHxS was associated with any type of dyslipidemia.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Relationships Between Serum Levels of Per- and Polyfluoroalkyl Substances and Obesity-Related Conditions in Patients of Okinawa, Japan

  • 期刊论文

  • 发表日期：

    2025年7月7日

查看全文
  • Misa Tomono,
  • Shinto Ando,
  • Kouji H. Harada,
  • Zhaoqing Lyu,
  • Mariko Harada Sassa,
  • Takuhiro Moromizato,
  • Kei Nakamura,
  • Kunitoshi Iseki,
  • Chiho Iseki,
  • Chikashi Takara,
  • Hiroshi Nakamura,
  • Masami Kawamura,
  • Haruka Tokuda,
  • Ché Matthew Harris,
  • Yasuharu Tokuda

摘要

Per- and polyfluoroalkyl substances (PFAS) are human-made chemicals used in various manufactured products that accumulate in the environment and human bodies. We examined associations between serum PFAS levels and obesity or obesity-related clinical conditions using data from participants in Okinawa Island, a region in Japan with high PFAS exposure. We conducted a cross-sectional study using blood samples and clinical data from outpatients in a large primary care clinic. Linear regression analysis investigated the relationship between serum PFAS levels and body mass index (BMI) or other obesity-related clinical conditions. We also conducted modified Poisson models with robust standard errors analysis with serum PFAS levels for overweight, obesity, dyslipidemia, and hypertension. Of 399 participants, mean serum levels of perfluorooctanoic acid (PFOA) and perfluorooctane sulfonate (PFOS) were 2.80 ng/mL (SD, 1.93) and 7.56 ng/mL (SD, 5.83), respectively. Increased serum levels of PFAS were not associated with higher BMIs. Higher serum levels of perfluorohexane sulfonate (PFHxS) were related to a lower level of high-density lipoprotein cholesterol (HDLC) [Beta coefficient: − 1.90 ng/mL (95% CI − 3.33 to − 0.48)]. No adverse associations were found between higher serum PFAS levels and triglycerides, alanine transaminase, or low-density lipoprotein cholesterol. Only high serum PFHxS had a statistically significant odds ratio of 1.91 ng/mL (95% CI, 1.08–3.38; p = 0.04) on dyslipidemia, but no other adverse relations were found between PFAS levels and overweight, obesity, and hypertension. Greater PFAS levels were not associated with obesity in our participants. However, PFHxS and PFOA were related to lower levels of HDLC, and PFHxS was associated with any type of dyslipidemia.